Brief: Kazia Therapeutics Announces Granting Of Type C Meeting With FDA To Discuss Potential Next Steps For Paxalisib In The Treatment Of Newly Diagnosed Glioblastoma Multiforme
04/11/2024 13:30
Nov 4 (Reuters) - Kazia Therapeutics Ltd KZIA.O :
* KAZIA THERAPEUTICS ANNOUNCES GRANTING OF TYPE C MEETING
WITH FDA
TO DISCUSS POTENTIAL NEXT STEPS FOR PAXALISIB IN THE TREATMENT
OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
* KAZIA THERAPEUTICS LTD - FULL DATA FROM PAXALISIB ARM
EXPECTED
LATER THIS YEAR
Source text: ID:nPngVfZma
Further company coverage: KZIA.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering